NeuroOne Q2 FY2024 product revenue triples to $1.38M; OneRF ablation system launched

NEUROONE MEDICAL TECHNOLOGIES Corp

2024-Q2 EPS reported -$0.25 revenue$2,354,943

Product revenue $1.38M in Q2 2024, up from $466K in Q2 2023.
Net loss narrowed to $2.9M vs $3.5M a year ago; six-month net loss $6.2M.
Cash and cash equivalents $2.4M as of March 31, 2024, down from $5.3M at Sept 30, 2023.
Initiated limited commercial launch of OneRF Ablation System in late March; 5 patients implanted.
Zimmer Biomet continued expanding sEEG electrode accounts; raised $2.0M via ATM in Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEUROONE MEDICAL TECHNOLOGIES Corp reported second quarter fiscal year 2024 ended March 31, 2024 results: revenue $1,377,000, net income $2.9 million.

Period: second quarter fiscal year 2024 ended March 31, 2024
Revenue: $1,377,000
Net income: $2.9 million
Result: reported results

Exact text from the filing

results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: ● Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023 ● Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo ® sEEG: ● Zimmer Biomet continued to expand into new

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-042938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.